Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Weekly somapacitan versus daily growth hormone replacement and glucose variability in adult growth hormone deficiency
jRCT1031210321Completed
- Sponsor
- Growth Science
- Start
- Dec 2021
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label, single-arm trial of somapacitan and somatropin in adult onset growth hormone deficiency (AGHD), sponsored by Growth Science. Primary endpoint: Mean amplitude of glycemic excursions. Started Dec 2021; status: completed.
02
Drugs
somapacitansomatropin
03
Conditions
adult onset growth hormone deficiency (AGHD)
Beyond the preview
Go deeper on jRCT1031210321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1031210321.